Australia | Apr 18 2006
The inability to rid the body of excess iron is one of the world’s most common hereditary disorders. Iron overload disorders are suffered by approximately 11 million people worldwide. 150,000 of these live in Canada, where Resonance Health (RHT) has just been granted regulatory clearance for its "novel, non-evasive diagnostic test".
Resonance Health is an Australian healthcare company specialising in the development and commercialisation of magnetic resonance imaging (MRI) related technology for the quantitative measurement of iron levels in the body. In 2005 Resonance launched FerriScan, which has become a world-leading tool for measuring liver iron levels.
Canadian regulatory approval has now followed that of the Australia, the US and Europe.
Resonance sees Canada as a "significant milestone" due to the sophistication of its market. It believes the Canadian market will be a strategic segment in the overall achievement of the business goals for FerriScan.
Resonance Health last traded at $0.51.

